Summary
Danaher Corporation (DHR) reported flat total sales for the fiscal year ended December 30, 2024, with a 1.5% decrease in core sales. This performance was influenced by a 2.0% boost from acquisitions, which partially offset declines in the Biotechnology and Life Sciences segments, while the Diagnostics segment showed growth. Net earnings from continuing operations declined to $3.9 billion from $4.2 billion in the prior year, impacted by intangible asset impairments and increased operating expenses. The company's strategic priorities remain focused on strengthening competitive advantage through the Danaher Business System (DBS), enhancing its portfolio via strategic capital allocation, and attracting top talent. Looking ahead, Danaher has initiated a cost savings program expected to generate at least $150 million in annual pre-tax savings starting in Q1 2025. The company also continues to manage its capital structure, evidenced by significant share repurchases totaling $6.0 billion in 2024. Despite a challenging macro-economic environment, including global economic uncertainty and inflationary pressures, Danaher's diversified business model across life sciences, diagnostics, and biotechnology sectors provides a degree of resilience.
Financial Highlights
53 data points| Revenue | $23.88B |
| Cost of Revenue | $9.67B |
| Gross Profit | $14.21B |
| R&D Expenses | $1.58B |
| SG&A Expenses | $7.76B |
| Operating Income | $4.86B |
| Net Income | $3.90B |
| EPS (Basic) | $5.33 |
| EPS (Diluted) | $5.29 |
| Shares Outstanding (Basic) | 731.00M |
| Shares Outstanding (Diluted) | 737.20M |
Key Highlights
- 1Total sales remained flat year-over-year for the fiscal year ended December 30, 2024, while core sales decreased by 1.5%.
- 2Net earnings from continuing operations decreased to $3.9 billion from $4.2 billion in the prior year, impacted by intangible asset impairments and higher operating expenses.
- 3The company initiated a cost savings program in Q1 2025 targeting at least $150 million in annual pre-tax savings.
- 4Danaher repurchased approximately $6.0 billion of its common stock in fiscal year 2024.
- 5The Biotechnology segment experienced a 6.0% sales decline, primarily due to decreased core sales in bioprocessing, while the Diagnostics segment saw a 2.0% sales increase driven by core growth.
- 6The Life Sciences segment reported a 2.5% sales increase, largely due to acquisitions, but faced a core sales decline.
- 7Geographically, North America showed strength with increased sales in developed markets, while high-growth markets, particularly China, experienced a decline in core sales.
- 8The company ended the year with $2.1 billion in cash and cash equivalents and maintained a strong liquidity position with a $5.0 billion revolving credit facility.